Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises

Company Overview - Organovo Holdings, Inc. is a clinical stage biotechnology company focused on developing novel treatment approaches for inflammatory bowel disease (IBD) [1] - The company utilizes proprietary technology to create three-dimensional (3D) human tissues that replicate key aspects of native human tissue composition, architecture, function, and disease [2] Recent Developments - Organovo announced the issuance of an additional 2,967,144 shares of common stock due to warrant exercises by investors and at-the-market stock sales [1] - The gross proceeds from these activities are expected to total approximately $2.3 million before financial advisory fees and commissions [1] - Following this issuance, the total number of outstanding shares of common stock will be 20,421,617 [1]